This listing is provided strictly for in vitro laboratory research. It is not a drug, supplement, food, or medical product, is not for human or veterinary use, and has not been evaluated by the FDA. By purchasing you certify that you are at least 21 years of age and a qualified researcher acquiring this material solely for lawful laboratory research.
CL-AMY
A fatty-acid-conjugated amylin analogue engineered for extended receptor engagement at the amylin receptor (AMYR) and calcitonin receptor (CTR). Studied in metabolic research as a complement to incretin receptor agonists; preclinical models examine satiety signaling, gastric emptying, and glucagon suppression.
Free COA included · Free shipment protection · 99%+ purity by HPLC & MS · Lyophilized powder
Certificate of Analysis — Included Free
Every batch independently tested by U.S.-accredited labs. Lot-matched COA confirms identity, purity ≥99% by HPLC, and safety screening.
Research Overview
CL-AMY is a long-acting amylin analogue designed for sustained engagement of amylin receptors (AMYR1–3) and the calcitonin receptor. Native amylin (IAPP) is co-secreted with insulin from pancreatic beta cells and contributes to post-prandial glucagon suppression, gastric motility modulation, and central satiety signaling. CL-AMY's structural modifications confer albumin binding and substantially extended pharmacokinetic profiles in rodent models.
In vitro research has characterized CL-AMY's binding affinities at AMY1R, AMY2R, AMY3R, and CTR compared to native amylin, examining differences in receptor selectivity and signaling bias. Cell-based cAMP and calcium flux assays have been used to profile its downstream signaling.
CL-AMY is most frequently studied in combination with incretin receptor agonists, investigating whether simultaneous engagement of amylin and incretin receptors produces additive or synergistic effects on energy intake, body weight, and plasma glucose in diet-induced obesity models. Research has also examined its effects on hypothalamic neuropeptide circuits involved in food intake regulation.
All referenced studies are preclinical or in vitro. Not for human use.
Molecular Information
| Full Name / IUPAC | CL-AMY |
| CAS Number | 2390571-99-4 |
| Molecular Formula | C₁₆₈H₂₆₆N₄₆O₅₅S₂ |
| Molecular Weight | ~3,900 g/mol (estimated) |
| Sequence / Structure | 37-aa amylin analogue; C20 FA conjugate |
| Appearance | White lyophilized powder |
| Solubility | Soluble in sterile water; may require gentle warming |
| Format | Lyophilized (freeze-dried) powder |
| SKU | CL-AMY |
Quality & Testing
- Purity: ≥99% by HPLC
- Identity: Confirmed by Mass Spectrometry (LC-MS)
- Heavy Metals: Screened; below detection thresholds
- Endotoxin: Tested per LAL assay
- Lot Tracking: Lot number on every vial matches published COA
- Packaging: Nitrogen-purged, sealed glass vials
Storage & Handling
- Short-term: Room temperature (15–25°C), dry, dark — up to 4 weeks
- Long-term: Refrigerated at 2–8°C — up to 18 months lyophilized
- Extended: −20°C; avoid freeze-thaw cycling
- Store lyophilized at −20°C. Reconstitute in sterile water; use within 30 days at 4°C.
This compound is supplied for in vitro research and laboratory use only. It is not for human or veterinary use, is not a drug or dietary supplement, and has not been evaluated or approved by the FDA or any regulatory agency for any therapeutic application. Purchasers must be 18 years of age or older and qualified researchers operating in compliance with all applicable local, state, and federal regulations governing research chemicals.
